Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;30(2):129-141.
doi: 10.1007/s11248-020-00232-9. Epub 2021 Feb 20.

Mini review: genome and transcriptome editing using CRISPR-cas systems for haematological malignancy gene therapy

Esther K Elliott  1 , Larisa M Haupt  1 , Lyn R Griffiths  2
Affiliations
Review

Mini review: genome and transcriptome editing using CRISPR-cas systems for haematological malignancy gene therapy

Esther K Elliott et al. Transgenic Res. 2021 Apr.

Abstract

The recent introduction of clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR associated protein (Cas) systems, offer an array of genome and transcriptome editing tools for clinical repair strategies. These include Cas9, Cas12a, dCas9 and more recently Cas13 effectors. RNA targeting CRISPR-Cas13 complexes show unique characteristics with the capability to engineer transcriptomes and modify gene expression, providing a potential clinical cancer therapy tool across various tissue types. Cas13 effectors such as RNA base editing for A to I replacement allows for precise transcript modification. Further applications of Cas13a highlights its capability of producing rapid diagnostic results in a mobile platform. This review will focus on the adaptions of existing CRISPR-Cas systems, along with new Cas effectors for transcriptome or RNA modifications used in disease modelling and gene therapy for haematological malignancy. We also address the current diagnostic and therapeutic potential of CRISPR-Cas systems for personalised haematological malignancy.

Keywords: CRISPR1; Cas4; Gene-therapy3; Genome-editing2; Malignancy6; Transcriptome5.

PubMed Disclaimer

References

    1. Abudayyeh, O. O., Gootenberg, J. S., Konermann, S., Joung, J., Slaymaker, I. M., Cox, D. B., Zhang, F. (2016). C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science, 353(6299), aaf5573. doi: https://doi.org/10.1126/science.aaf5573
    1. Abudayyeh OO, Gootenberg JS, Essletzbichler P, Han S, Joung J, Belanto JJ, Zhang F (2017) RNA targeting with CRISPR-Cas13. Nature 550(7675):280–284. https://doi.org/10.1038/nature24049 - DOI - PubMed - PMC
    1. Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, Liu DR (2019) Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576(7785):149–157. https://doi.org/10.1038/s41586-019-1711-4 - DOI - PubMed - PMC
    1. Bhaya D, Davison M, Barrangou R (2011) CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation. Annu Rev Genet 45:273–297. https://doi.org/10.1146/annurev-genet-110410-132430 - DOI - PubMed
    1. Bradshaw G, Lualhati RR, Albury CL, Maksemous N, Roos-Araujo D, Smith RA, Griffiths LR (2018) Exome sequencing diagnoses X-linked Moesin-associated immunodeficiency in a primary immunodeficiency case. Front Immunol 9:420. https://doi.org/10.3389/fimmu.2018.00420 - DOI - PubMed - PMC

Publication types

LinkOut - more resources